Clinical trials: Respiratory Syndrome, Acute, Severe
SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)
Methylprednisolone in COVID-19 Patients (Methyl19LGH)
In COVID-19 deep airway and alveolar destruction occurred due to inflammatory reaction resulting into severe pneumonia. In COVID-19, lung injury is not only due to viral damage to tissue, but it is also due to immune response…
- Trial name
- Methyl19LGH (NCT04559113)
- Testing
- Methylprednisolone Injectable Product
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Lahore General Hospital
COVID-19, Households
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
The goal of this project is to understand the household level transmission dynamics and factors that predict transmission of SARS-COV-2 between pediatric and adults in the household.
- Conditions
- COVID-19, Households, SARS CoV 2 Infection
- Trial name
- NCT05467917
- Where
- United States
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Columbia University
SARS-CoV-2 Infection, Kidney Transplant Infection
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highly contagious viral disease, the condition of which main clinical symptoms are characterized by fever and respiratory symptoms.
- Trial name
- NCT04494776
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Helio Tedesco Silva Junior
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
Severe Acute Respiratory Distress Syndrome, Refractory Hypoxemia
ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure
Extracorporeal membrane oxygenation (ECMO) had been used to treat refractory hypoxemia associated with acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04031794
- Testing
- Extra Corporeal Membrane Oxygenator (ECMO)
- Where
- Thailand
- Volunteers
- 250 people
- Sponsor
- Mahidol University
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
The intersectoral platform is part of the National Pandemic Cohort Network (NAPKON) and will be used to provide a comprehensive and harmonized collection of data and biomaterial for researchers from national consortia…
- Trial name
- SUEP-NAPKON (NCT04768998)
- Testing
- Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
- Where
- 34 sites in Germany
- Volunteers
- 6,550 people
- Sponsor
- Goethe University
Coronavirus
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease…
- Trial name
- NCT04385836
- Testing
- alpha one antitrypsin inhalation
- Where
- Saudi Arabia
- Volunteers
- 150 people
- Sponsor
- Ministry of Health, Saudi Arabia
Vaccination Hesitancy
Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination
The objective of this study is to evaluate the preliminary efficacy and acceptability of an mobile Health-based motivational interviewing (MI) intervention to promote SARS-CoV-2 vaccination (MOTIVACC) compared to traditional…
- Trial name
- COVID-19 (NCT05977192)
- Testing
- Standard MI, Intensive MI, MOTIVACC
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oklahoma State University
Multi-organ Failure After Severe Trauma
Metabolic Reprogramming in Renal Tubular Cells in Acute Kidney Injury Following Severe Trauma
Severe trauma remains the leading cause of death in people under 50, and is associated with high morbidity, including severe disability, with a substantial socio-economic impact.
- Trial name
- METAKIT (NCT06167512)
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Severe Respiratory Failure, Acute Respiratory Distress Syndrome
Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE
We wish to prospectively assess the burden of, management and therapeutic approaches to, and outcomes from acute hypoxaemic respiratory failure requiring ventilatory support, during the winter months in both the northern and…
- Trial name
- LUNG-SAFE (NCT02010073)
- Where
- Belgium
- Volunteers
- 14,000 people
- Sponsor
- European Society of Intensive Care Medicine
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
D1. Primary Objective: 1. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies D2. Secondary Objectives: 1.
- Conditions
- Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT04748185
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Mayo Clinic
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
SARS-CoV 2
Association Between BMI and COVID-19
This study will involve collection of pseudonymized data from hospital-based data reporting at multiple international sites. Collating data from a large volume of patients with COVID-19 admitted in ICU across multiple…
- Trial name
- BMI-SARS-CoV-2 (NCT04391738)
- Testing
- Patients admitted to Intensive Care Unit with SARS-CoV2
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Lille
Multiple Sclerosis (MS)
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
The primary objective of this study is to document immunization status of MS participants after SARS-CoV-2-vaccinations and to evaluate possible effects of disease modifying therapy (DMTs) on the immune status.
- Trial name
- NCT05197699
- Where
- 12 sites in Germany
- Volunteers
- 160 people
- Sponsor
- Biogen
COVID-19, Vaccine Reaction
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
In this phase 1 study, the inactivated virus vaccine National Research Centre (NRC) Vaccine-101 (VACC-101) will be investigated for its safety and immunogenicity in healthy volunteers with the aim of providing effective and safe…
- Conditions
- COVID-19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- NCT05128721
- Testing
- Covi Vax
- Where
- Egypt
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Research Centre, Egypt
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
SARS-CoV Infection
Remdesivir in COVID-19 Lahore General Hospital
Remdesivir is a monophosphoramidate prodrug of an adenosine analogue and it has a broad-spectrum antiviral activity against paramyxoviruses, falviviruses and coronaviruses.
- Trial name
- RC19LGH (NCT04560231)
- Testing
- Remdesivir
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Lahore General Hospital
Covid-19
Antioxidant Therapy for COVID-19 Study
Finding effective strategies to treat or prevent the novel coronavirus disease that started in 2019 (COVID-19) is a global public health priority.
- Trial name
- GSHSOD-COVID (NCT04466657)
- Testing
- Antioxidation Therapy, Standard of Care
- Where
- 11 sites in Nigeria
- Sponsor
- Obafemi Awolowo University
SARS-CoV 2
Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly
In most diseases, older people have less typical symptomatology than that described for younger people. The investigators therefore hypothesize that within the framework of coronavirus disease 19, the clinical pictures in the…
- Trial name
- CovAged (NCT04414319)
- Where
- 5 sites in France, Guadeloupe and 1 more
- Volunteers
- 170 people
- Sponsor
- University Hospital Center of Martinique